MIP 3
Alternative Names: C-C motif chemokine 23, CCL23, Small-inducible cytokine A23, SCYA23, Macrophage inflammatory protein 3, MIP-3, Myeloid progenitor inhibitory factor 1, MPIF-1, CK-beta-8, CKb8, CKB-8, Ckb-8-1.
- Sku: PSB-chm-358-5µg
- Vendor: ProSpec-Tany
Contact us directly for international purchases.
Product Description
Recombinant Human Macrophage Inflammatory protein-3 (CCL23) is a chemokine belonging to the CC subfamily. It plays a role in the recruitment and activation of monocytes, dendritic cells, and lymphocytes in the immune response. With a molecular weight of approximately 8.7 kDa, CCL23 is involved in inflammatory processes and has been implicated in various diseases such as asthma, rheumatoid arthritis, and cancer. Its function in regulating immune cell trafficking makes it a valuable target for therapeutic interventions.
Current Lead Time
7-14 Days
Product Specifications
Species |
Human |
Expression System | E. coli |
Purity | 97.0% by SDS-PAGE |
Activity |
Determined by its ability to chemoattract human T cell population using a concentration range of 10-50ng/ml corresponding to a Specific Activity of 20,000-100,000IU/mg. Determined by its ability to chemoattract human T cell population using a concentration range of 10-50ng/ml corresponding to a Specific Activity of 20,000-100,000IU/mg. |
Activity Assay | |
Animal Component Free (ACF) | Yes |
Molecular Weight |
11.3 kDa |
Structure | Dimer |
Endotoxin Concentration |
Not Available |
Purification Method | Not Available |
Form |
Lyophilized |
Formulation | Filtered (0.2µm) and lyophilized from a concentrated (1mg/ml) solution in 20mM PB, pH 7.4, 150mM NaCl. |
*For Research Use Only
If your product is within its expiration period, and has not performed according to expectations, fill out the sample return form. Return the unused sample frozen, with the auto generated packing slip to the address on the instructions. You will receive a full refund along with a replacement of the unused portion (inclusive of the failed test). Damages do not cover any additional costs incurred for failed experimentation.
Have a question?
MIP 3